Breast secretory carcinoma

Summary

Breast secretory carcinoma (MONDO:0003208) is a cancer and 1 clinical trial. Molecularly, ETV6::NTRK3 Fusion confers sensitivity to Larotrectinib in Breast Secretory Carcinoma (CIViC Level C). Top therapeutic interventions include nivolumab. A subtype of invasive ductal breast carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 1
• Precision-medicine evidence (CIViC): 1 subtype–drug association

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	breast secretory carcinoma
Mondo ID	MONDO:0003208
MeSH	C537535
DOID	DOID:4922
NCIT	C4189
UMLS	C0334371
MedGen	87226
Is cancer (heuristic)	yes

Also known as: cystic hypersecretory breast carcinoma · cystic hypersecretory carcinoma of breast · cystic hypersecretory carcinoma of the breast · infiltrating cystic hypersecretory duct breast carcinoma · invasive cystic hypersecretory duct breast carcinoma · JSCB · juvenile breast carcinoma · juvenile carcinoma (formerly) · juvenile carcinoma of breast · juvenile carcinoma of the breast · juvenile carcinoma of the breast (morphologic abnormality) · juvenile secretory breast carcinoma · juvenile secretory carcinoma of breast · juvenile secretory carcinoma of the breast · SBC · secretory breast carcinoma · secretory carcinoma · secretory carcinoma of breast · secretory carcinoma of the breast

Disease family

This is a subtype of invasive ductal breast carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › integumentary system cancer › breast adenocarcinoma › breast ductal adenocarcinoma › invasive ductal breast carcinoma › breast secretory carcinoma

Related subtypes (9): breast mucinous carcinoma, glycogen-rich clear cell breast carcinoma, acinic cell breast carcinoma, invasive tubular breast carcinoma, scirrhous breast carcinoma, basal-like breast carcinoma, invasive ductal and lobular carcinoma, medullary breast carcinoma, pleomorphic breast carcinoma

Subtypes (1): breast cystic hypersecretory carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06638931	PHASE2	RECRUITING	Agnostic Therapy in Rare Solid Tumors

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
NIVOLUMAB	4	1

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 1 predictive associations from 1 curated evidence items; also 4 diagnostic, 1 oncogenic.

Molecular subtype	Therapy	Effect	Level	CIViC
ETV6::NTRK3 Fusion	Larotrectinib	Sensitivity/Response	CIViC C	EID6475